Asthma and Allergy News and Research

GlaxoSmithKline Study Shows Nucala Improves Quality of Life, Lung Function in Severe Asthma

GlaxoSmithKline plc (LSE/NYSE:GSK) today announced data demonstrating that severe asthma patients, whose disease is driven by eosinophilic inflammation, treated with first-in-class biologic Nucala® (mepolizumab) added-on to standard of care, achieved clinically and statistically significant improvements in their health-related quality of life and lung function, when compared to patients treated with placebo and standard of care. These results are from the phase IIIb MUSCA study (NCT02281318, 200

Black Children Six Times More Likely to Die of Asthma

There is no cure for asthma, but with the proper diagnosis, medication and an asthma management plan, symptoms can be controlled. When not properly controlled asthma can be deadly. A study being presented at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting called “Where Do Children with Asthma Die? A National Perspective from 2003 to 2014” seeks to address where and which demographics of children are dying because of asthma in the United States.

Add Your Voice to Asthma Research

We know that everyone’s asthma is different and we would like to hear about your unique experiences about living with asthma. This research will give us insight on issues affecting quality of life and treatments for asthma. It will also help us raise awareness about living with asthma and improve our education materials. The My Life With Asthma online survey will take about 20 minutes to complete. Your identity and responses will be anonymous. After you take the survey, you can enter your...

Xyzal Allergy 24HR Approved for Over the Counter Use

Antihistamine Offers 24-Hour Relief to Adults and Children with Seasonal and Year-Round Allergies [Press Release] BRIDGEWATER, N.J. /PRNewswire/ -- Sanofi announced that the U.S. Food and Drug Administration (FDA) approved Xyzal® Allergy 24HR as an over-the-counter (OTC) treatment for the relief of symptoms associated with seasonal and year-round allergies. Specifically, two formulations of Xyzal are now approved for OTC use – 5 mg tablets for ages 6 years and older, as well as 0.5 mg/mL...

FDA Approves Spiriva Respimat to Treat Asthma In Children Ages 6-12

[Press Release] FDA Expands Approval of SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray for Maintenance Treatment of Asthma in Children Steroid-free SPIRIVA RESPIMAT now approved as asthma treatment for age 6 and older Supplemental New Drug Application (sNDA) approved under priority review from the FDA FDA also granted pediatric exclusivity to SPIRIVA RIDGEFIELD, Conn., Feb. 16, 2017 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and...

FDA Warns About Potential Allergic Reactions With the Skin Antiseptic Chlorhexidine Gluconate

The U.S. Food and Drug Administration (FDA) is warning that rare but serious allergic reactions have been reported with the widely used skin antiseptic products containing chlorhexidine gluconate. Although rare, the number of reports of serious allergic reactions to these products has increased over the last several years.

FDA Approves Two New Asthma Inhalers

[Press Release] Teva Announces FDA Approval of Two New RespiClick® Maintenance Inhalers for the Treatment of Asthma Approvals Expand Portfolio of Respiratory Medicines Delivered in RespiClick® Inhaler Designed to Eliminate the Need for Hand-Breath Coordination During Inhalation JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) announced that the U.S. Food and Drug Administration (FDA) approved two products for adolescent and adult patients with asthma.

AAFA Names 15 States to 2016 State Honor Roll™ of Asthma and Allergy Policies for Schools

The 2016 State Honor Roll™ of Asthma and Allergy Policies for Schools (SHR) report identifies states that make it a priority to create healthy school settings for students with asthma and allergies. This annual report lists states with comprehensive laws and policies aimed at keeping children with asthma and allergies healthy at school.

Mylan Launches Authorized Generic for EpiPen® (epinephrine injection, USP) Auto-Injector

[Press Release] Mylan Launches the First Generic for EpiPen® (epinephrine injection, USP) Auto-Injector as an Authorized Generic Authorized Generic Offered at More Than 50% Below Wholesale Acquisition Cost of EpiPen Auto-Injector HERTFORDSHIRE, England and PITTSBURGH, Dec. 16, 2016 / PRNewswire / -- Mylan N.V. (NASDAQ, TASE: MYL) today announced the launch of the authorized generic for EpiPen ® (epinephrine injection, USP) Auto-Injector at a wholesale acquisition cost (WAC) of $300 per...

The 2016 Fall Allergy Capitals: How Does Your City Rank?

Did you know that fall allergies can be just as bad as spring allergies? Our 2016 Fall Allergy Capitals TM report identifies the most challenging places to live with fall allergies among the 100 largest metropolitan areas in the U.S. This report is your guide to help prevent and manage allergy symptoms if you live in one of these cities. Here is our top five national list of the most challenging cities: Jackson, Mississippi Memphis, Tennessee McAllen, Texas Louisville, Kentucky Syracuse, New...

AAFA Co-Sponsored Report Provides Recommendations for Food Allergy Research, Treatment, and Policy

[Press Release] PR Contact: Adam Bailine, Vice President, Marketing & Communications (202) 466-7643, ext. 254 abailine@aafa.org AAFA Co-Sponsored Report Provides Recommendations for Food Allergy Research, Treatment, and Policy With support from the Asthma and Allergy Foundation of America (AAFA), the National Academies of Sciences, Engineering, and Medicine releases a monumental report that makes recommendations to increase our understanding of and approaches to food allergies November...

×
×
×
×